在轻度认知障碍和阿尔茨海默病中基于任务的fMRI大脑激活:ALE元分析
Zheng Long Lee1, Jesse Jianyi Li2,3, Savannah Kiah Hui Siew2
1Psychology, School of Social Sciences, Nanyang Technological University, Singapore, 639818, Singapore. zlee049@e.ntu.edu.sg.
GeroScience
|August 29, 2025
概括
阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 在认知任务中显示异常的大脑活化. 这一元分析揭示了这些异常的空间趋同,特别是在注意力和前面对面网络中.
科学领域:
- 神经科学
- 认知神经学
- 医学成像
背景情况:
- 基于任务的fMRI研究揭示了阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的异常激活模式.
- 这些模式与这些神经认知障碍的认知处理受损有关.
- 之前的分析可能因错误的阳性结果而受到限制.
研究的目的:
- 提供基于任务的fMRI研究的更新元分析.
- 为了确定异常大脑激活和低激活的空间趋同.
- 使用元分析功能解码推断观察到的激活模式的功能相关性.
主要方法:
- 基于坐标的激活概率估计 (ALE) 的元分析.
- 包括90项符合条件的研究,共有2824名参与者.
- 集群级别的家族级别错误纠正和元分析功能解码.
主要成果:
- 在MCI和健康对照者 (HC) 中发现了与背部注意力和前侧对象网络相关的显著激活集群,涉及到所有记忆和所有任务.
- 功能解码将这些集群与空间和语音处理联系起来.
- 在AD中,显著的激活汇聚在上环中,与体运动网络重叠并与听觉功能相关.
结论:
- 这一元分析说明了AD和MCI中异常任务相关激活和低激活的空间趋同.
- 这些发现突显了在这些条件下广泛的认知任务中的非典型神经认知处理.
- 这项研究完善了我们对AD和MCI认知障碍的神经生物学基础的理解.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
10:09Transferring Cognitive Tasks Between Brain Imaging Modalities: Implications for Task Design and Results Interpretation in fMRI Studies
Published on: September 22, 2014
13.3K
相关概念视频
01:26Alzheimer's Disease: Overview
1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
01:22Alzheimer's Disease: Treatment
513
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
513